SBC Medical Boosts Margins and Announces Share Buyback Amid Global Aesthetic Medicine Expansion
SBC Medical Group Holdings reported improved first-quarter financial performance, increasing earnings per share and EBITDA margins while strategically positioning itself for growth in the global cosmetic surgery market through clinic expansion and a new share buyback program.
SBC Medical Group Holdings has demonstrated financial resilience and strategic growth in the first quarter of 2025, reporting enhanced profitability and a commitment to expanding its global aesthetic medicine footprint. The company saw earnings per share increase 5% year-over-year to $0.21, with EBITDA margins rising from 46% to 52%.
Despite a challenging marketplace in Japan, SBC Medical expanded its clinic network to 251 locations, a 16.8% increase from the previous year. The company also grew its customer base by 14% to 6.1 million, with 71% of customers returning to franchisee clinics multiple times during the quarter.
CEO Yoshiyuki Aikawa emphasized the company's strategic focus on enhancing its platform and optimizing profitability through revised pricing strategies. While revenue declined 14% to $47 million, largely due to divesting non-core businesses, net income increased 15% year-over-year.
To further signal confidence in its growth trajectory, SBC Medical announced a $5 million share buyback program running from May 20, 2025, to May 20, 2026. The company believes its current stock price undervalues its performance and potential in a global cosmetic surgery market projected to grow at a 14.7% compound annual growth rate.
The company's expansion strategy includes making aesthetic medicine more accessible, offering advanced treatments, and entering new markets like the United States and Singapore. With the global cosmetic surgery market valued at $122.08 billion in 2022, SBC Medical is positioning itself to capitalize on emerging opportunities in aesthetic medical services.